Intrommune Therapeutics, Inc., a clinical stage biotechnology company, has successfully completed the final visit of the last patient in the Phase 1 OMEGA Clinical Study for individuals with peanut allergy. This 48-week trial is specifically designed for adults with peanut allergies and aims to gather long-term safety data while determining the appropriate starting dose for INT301, an innovative immunotherapy for peanut desensitization. The results obtained from this trial will contribute to a better understanding of the clinical profile of INT301.
Michael Nelson, CEO of Intrommune Therapeutics, expressed his satisfaction with achieving Last Patient Last Visit, considering it a significant milestone for the company's ongoing efforts in developing groundbreaking products to address food allergies. Based on the preliminary analysis of blinded data, patients participating in the OMEGA Clinical Study have only experienced temporary adverse events related to the drug, without any serious adverse events or instances of anaphylaxis. Additionally, there has been no need for emergency epinephrine administration. The comprehensive safety and efficacy results are expected to be presented during the fourth quarter of this year.